Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 1;16(21):3762.
doi: 10.3390/nu16213762.

Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals

Felix Harpain  1 , Slobodan Milicevic  2 , Lucy Howard  3 , Patricia Biedermann  2 , Ulrich-Frank Pape  4   5
Affiliations

Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals

Felix Harpain et al. Nutrients. .

Abstract

Background: This study aimed to gain real-world insights from healthcare professionals (HCPs) regarding the management of adult patients with short bowel syndrome and intestinal failure (SBS-IF) who received teduglutide and achieved parenteral support (PS) independence or PS volume stability for ≥12 months.

Methods: This cross-sectional survey was conducted in five European countries and Canada via a self-reported questionnaire (November 2022-March 2023) among HCPs who manage patients with SBS-IF and who had prescribed teduglutide to ≥5 patients with SBS-IF receiving PS.

Results: Of the 70 HCPs who completed the survey, almost all reported managing patients with SBS-IF who achieved PS independence or PS volume stability (99%, 69/70 and 97%, 68/70, respectively) and maintained the standard teduglutide dose, without changes. A total of 52 HCPs managed patients who achieved PS independence and discontinued teduglutide. Of these HCPs, 73% (38/52) anticipated that these patients would remain PS-independent, not requiring PS reintroduction. Of the remainder, 79% (11/14) estimated that ≤40% of these patients would require PS reintroduction. While many HCPs (81%, 42/52) would reintroduce teduglutide in patients who discontinued its use after achieving PS independence, none would do so for patients who discontinued teduglutide after achieving PS volume stability if a patient's condition worsened.

Conclusions: This survey found that patients with SBS-IF can achieve PS independence or PS volume stability with teduglutide treatment. However, some HCPs (27%, 14/52) believe that a proportion of patients discontinuing teduglutide after achieving PS independence will require PS reintroduction. This survey suggests that teduglutide treatment should continue uninterrupted, unless clinically indicated, but this requires confirmation in future studies.

Keywords: intestinal failure; parenteral nutrition; short bowel syndrome; survey; teduglutide.

PubMed Disclaimer

Conflict of interest statement

F.H. received a grant and lecture fee from Takeda outside of the submitted work. S.M. and P.B. are employees of Takeda Pharmaceuticals International AG and hold Takeda stock or stock options. L.H. is an employee of Adelphi Real World, which received payment from Takeda Pharmaceuticals International AG as part of this research. U.-F.P. received consultation/lecture/advisory board honoraria and grant/research support from Takeda/Shire Pharmaceuticals/NPS Pharmaceuticals, received research support from Hanmi Pharma and Veciv Bio Pharma, and received consultation/advisory board honoraria and research support from Zealand Pharma.

Figures

Figure 1
Figure 1
Teduglutide dose strategy for patients with SBS-IF who achieved PS independence (A) or PS volume stability for ≥12 months (B) after teduglutide treatment. IF, intestinal failure; PS, parenteral support; SBS, short bowel syndrome.
Figure 2
Figure 2
Frequency of monitoring tests for patients with SBS-IF who achieved PS independence (A) or PS volume stability for ≥12 months (B) after teduglutide treatment. Data to the left of the bars represent the number of patients. Data next to the bars represent mean (standard deviation). IF, intestinal failure; PS, parenteral support; SBS, short bowel syndrome.
Figure 3
Figure 3
Tests performed to monitor patients with SBS-IF who achieved PS independence after initiating teduglutide treatment among patients who maintained teduglutide dose with no changes (A), who underwent teduglutide dose reduction (B), and who discontinued teduglutide (C). HCP, healthcare professional; IF, intestinal failure; PS, parenteral support; SBS, short bowel syndrome.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bioletto F., D‘Eusebio C., Merlo F.D., Aimasso U., Ossola M., Pellegrini M., Ponzo V., Chiarotto A., De Francesco A., Ghigo E., et al. Efficacy of teduglutide for parenteral support reduction in patients with short bowel syndrome: A systematic review and meta-analysis. Nutrients. 2022;14:796. doi: 10.3390/nu14040796. - DOI - PMC - PubMed
    1. Blüthner E., Pape U.F., Tacke F., Greif S. Quality of life in teduglutide-treated patients with short bowel syndrome intestinal failure-a nested matched pair real-world study. Nutrients. 2023;15:1949. doi: 10.3390/nu15081949. - DOI - PMC - PubMed
    1. Büttner J., Blüthner E., Greif S., Kühl A., Elezkurtaj S., Ulrich J., Maasberg S., Jochum C., Tacke F., Pape U.F. Predictive potential of biomarkers of intestinal barrier function for therapeutic management with teduglutide in patients with short bowel syndrome. Nutrients. 2023;15:4220. doi: 10.3390/nu15194220. - DOI - PMC - PubMed
    1. Pevny S., Maasberg S., Rieger A., Karber M., Blüthner E., Knappe-Drzikova B., Thurmann D., Büttner J., Weylandt K.H., Wiedenmann B., et al. Experience with teduglutide treatment for short bowel syndrome in clinical practice. Clin. Nutr. 2019;38:1745–1755. doi: 10.1016/j.clnu.2018.07.030. - DOI - PubMed
    1. Berghöfer P., Fragkos K.C., Baxter J.P., Forbes A., Joly F., Heinze H., Loth S., Pertkiewicz M., Messing B., Jeppesen P.B. Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL™) scale. Clin. Nutr. 2013;32:789–796. doi: 10.1016/j.clnu.2012.12.001. - DOI - PubMed

LinkOut - more resources